Drug intelligence / Profile preview

CD19 CAR-T cells-Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd-acute lymphoblastic leukemia

Development stage: Unknown
Lead developer: Shanghai Unicar-Therapy Bio-medicine Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Parenteral

Overview

Investigational **CD19-directed chimeric antigen receptor T-cell therapy** sponsored by Shanghai Unicar-Therapy Bio-medicine Technology for CD19-positive acute lymphoblastic leukemia. The registered consolidation study identifies the intervention only as \"CD19 CAR-T cells\" and evaluates it with separately administered CD19-positive feeder T cells in patients with acute lymphoblastic leukemia in remission; no unique product name, proprietary development code, CAR construct sequence, or commercial brand has been publicly disclosed for this exact intervention. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05381662?tab=researcher))

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CD19 CAR-T cells-Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd-acute lymphoblastic leukemia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19 CAR-T cells-Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd-acute lymphoblastic leukemia.

Explore the full profile